Tweet
Source: http://www.cidrap.umn.edu/news-persp...an-sep-21-2018
Stewardship / Resistance Scan for Sep 21, 2018
CARB-X growth; Carbapenem resistance in US hospitals; Data-sharing tool for antibiotic discovery
Filed Under:
Antimicrobial Stewardship
CARB-X report highlights growing portfolio, new partnerships
A new report from CARB-X highlights the progress the public-private partnership made in its second year of operation.
In its 2017-2018 "Progress Against Superbugs" annual report, released yesterday, CARB-X (the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator) says its portfolio of innovative antibiotics, rapid diagnostics, and alternative therapies to address the threat of drug-resistant bacteria nearly doubled during the fiscal year. As of Jul 31, CARB-X has awarded more than $91 million to 33 research projects in seven countries, including 10 new classes of antibiotics, five rapid-diagnostics projects, and 11 non-traditional therapeutics.
CARB-X also added two new funding partners in 2017-2018, with the UK government's Global Antimicrobial Resistance Innovation Fund committing ?20 million (US $26 million) and the Bill and Melinda Gates Foundation committing $25 million. They join current partners the Wellcome Trust, the Biomedical Advanced Research and Development Authority, and the National Institute of Allergy and Infectious Diseases. CARB-X now has more than $500 million to invest in antibacterial development.
"Looking to the year ahead, we will continue to fund the most innovative early development projects from around the world, focus our resources on the most urgent medical needs, and expand our global network of accelerators to support our growing portfolio," CARB-X executive director Kevin Outterson, JD, said in the report.
Sep 20 CARB-X annual report 2017-2018
Study finds high rate of carbapenem resistance in respiratory samples, ICUs
A review of gram-negative bacterial isolates from a large US hospital database has found that more than 3% were carbapenem non-susceptible, with high rates of non-susceptibility found in respiratory samples and intensive care units (ICUs). The findings were published today in Open Forum Infectious Diseases.
The retrospective cross-sectional study analyzed all non-duplicate Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter spp. isolates collected from patients at 358 US hospitals in 2017. Isolates were classified as carbapenem non-susceptible (Carb-NS) based on hospital reports of intermediate susceptibility or resistance to at least one of the following agents: ertapenem, imipenem, meropenem, or doripenem. The primary outcome was the rate of Carb-NS isolates as determined by local laboratory breakpoints and practices per routine clinical standard of care.
Of the 312,075 isolates tested, 10,698 Carb-NS pathogens (3.4%) were found. Respiratory samples were the most frequent source of Carb-NS isolates (35.3%), followed by urine (30.9%), skin/wound (23.6%), and blood (5.5%). P aeruginosa accounted for over half (58.8%) of all Carb-NS pathogens, followed by Enterobacteriaceae (30.2%). The pathogens with the highest rate of Carb-NS were Acinetobacter spp. (35.6%) and P aeruginosa (14.6%). The majority of Carb-NS pathogens were multidrug-resistant.
Analysis of care settings found that the rate of Carb-NS was significantly higher in ICU settings (5.4%) than in non-ICU settings (2.7%), although non-ICU settings had greater overall numbers. The difference remained significant in multivariable analysis after adjusting for infection and hospital characteristics (odds ratio, 1.35).
The authors of the study say that while overall Carb-NS rates are fairly low in US hospitals, the high rates found in certain sources (respiratory), pathogens (Pseudomonas and Acinetobacter), and settings (ICU) indicate that Carb-NS gram-negative bacteria continue to be an important problem in hospitals.
"We hope our data encourage hospitals to conduct evaluations at a facility level that can be used to guide local antimicrobial therapy," they write. "In addition to these efforts, continued research into therapeutic options to treat carbapenem-resistant infections is urgently needed, particularly for respiratory infections."
Sep 21 Open Forum Infect Dis abstract
Pew launches platform to help scientists working on antibiotic discovery
The Pew Charitable Trusts today launched a cloud-based, interactive data-sharing tool to help scientists advance research on new antibiotics.
Built by a team of antibiotic discovery experts from around the world, SPARK (Shared Platform for Antibiotic Research and Knowledge) aims to support the development of new antibiotics for gram-negative bacteria by integrating chemical and biological data from published studies as well as previously unpublished data, and making that data publicly available to scientists. The hope is that the platform will provide scientists in industry, academia, government, and the non-profit sector an opportunity to share data, learn from past research, and collaborate.
The idea for SPARK emerged from a 2016 Pew report on antibiotic discovery, which noted that scientists often cannot build on past work because much of the research is scattered across academic journals and industry archives, or not published at all. Pew announced its intention to build the platform in August 2017.
Interested researchers can request access to SPARK on the Pew website.
Sep 21 Pew press release
Aug 21, 2017 CIDRAP News story "New data-sharing platform aims to boost antibiotic discovery"
Stewardship / Resistance Scan for Sep 21, 2018
CARB-X growth; Carbapenem resistance in US hospitals; Data-sharing tool for antibiotic discovery
Filed Under:
Antimicrobial Stewardship
CARB-X report highlights growing portfolio, new partnerships
A new report from CARB-X highlights the progress the public-private partnership made in its second year of operation.
In its 2017-2018 "Progress Against Superbugs" annual report, released yesterday, CARB-X (the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator) says its portfolio of innovative antibiotics, rapid diagnostics, and alternative therapies to address the threat of drug-resistant bacteria nearly doubled during the fiscal year. As of Jul 31, CARB-X has awarded more than $91 million to 33 research projects in seven countries, including 10 new classes of antibiotics, five rapid-diagnostics projects, and 11 non-traditional therapeutics.
CARB-X also added two new funding partners in 2017-2018, with the UK government's Global Antimicrobial Resistance Innovation Fund committing ?20 million (US $26 million) and the Bill and Melinda Gates Foundation committing $25 million. They join current partners the Wellcome Trust, the Biomedical Advanced Research and Development Authority, and the National Institute of Allergy and Infectious Diseases. CARB-X now has more than $500 million to invest in antibacterial development.
"Looking to the year ahead, we will continue to fund the most innovative early development projects from around the world, focus our resources on the most urgent medical needs, and expand our global network of accelerators to support our growing portfolio," CARB-X executive director Kevin Outterson, JD, said in the report.
Sep 20 CARB-X annual report 2017-2018
Study finds high rate of carbapenem resistance in respiratory samples, ICUs
A review of gram-negative bacterial isolates from a large US hospital database has found that more than 3% were carbapenem non-susceptible, with high rates of non-susceptibility found in respiratory samples and intensive care units (ICUs). The findings were published today in Open Forum Infectious Diseases.
The retrospective cross-sectional study analyzed all non-duplicate Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter spp. isolates collected from patients at 358 US hospitals in 2017. Isolates were classified as carbapenem non-susceptible (Carb-NS) based on hospital reports of intermediate susceptibility or resistance to at least one of the following agents: ertapenem, imipenem, meropenem, or doripenem. The primary outcome was the rate of Carb-NS isolates as determined by local laboratory breakpoints and practices per routine clinical standard of care.
Of the 312,075 isolates tested, 10,698 Carb-NS pathogens (3.4%) were found. Respiratory samples were the most frequent source of Carb-NS isolates (35.3%), followed by urine (30.9%), skin/wound (23.6%), and blood (5.5%). P aeruginosa accounted for over half (58.8%) of all Carb-NS pathogens, followed by Enterobacteriaceae (30.2%). The pathogens with the highest rate of Carb-NS were Acinetobacter spp. (35.6%) and P aeruginosa (14.6%). The majority of Carb-NS pathogens were multidrug-resistant.
Analysis of care settings found that the rate of Carb-NS was significantly higher in ICU settings (5.4%) than in non-ICU settings (2.7%), although non-ICU settings had greater overall numbers. The difference remained significant in multivariable analysis after adjusting for infection and hospital characteristics (odds ratio, 1.35).
The authors of the study say that while overall Carb-NS rates are fairly low in US hospitals, the high rates found in certain sources (respiratory), pathogens (Pseudomonas and Acinetobacter), and settings (ICU) indicate that Carb-NS gram-negative bacteria continue to be an important problem in hospitals.
"We hope our data encourage hospitals to conduct evaluations at a facility level that can be used to guide local antimicrobial therapy," they write. "In addition to these efforts, continued research into therapeutic options to treat carbapenem-resistant infections is urgently needed, particularly for respiratory infections."
Sep 21 Open Forum Infect Dis abstract
Pew launches platform to help scientists working on antibiotic discovery
The Pew Charitable Trusts today launched a cloud-based, interactive data-sharing tool to help scientists advance research on new antibiotics.
Built by a team of antibiotic discovery experts from around the world, SPARK (Shared Platform for Antibiotic Research and Knowledge) aims to support the development of new antibiotics for gram-negative bacteria by integrating chemical and biological data from published studies as well as previously unpublished data, and making that data publicly available to scientists. The hope is that the platform will provide scientists in industry, academia, government, and the non-profit sector an opportunity to share data, learn from past research, and collaborate.
The idea for SPARK emerged from a 2016 Pew report on antibiotic discovery, which noted that scientists often cannot build on past work because much of the research is scattered across academic journals and industry archives, or not published at all. Pew announced its intention to build the platform in August 2017.
Interested researchers can request access to SPARK on the Pew website.
Sep 21 Pew press release
Aug 21, 2017 CIDRAP News story "New data-sharing platform aims to boost antibiotic discovery"